Cerebrospinal fluid (CSF) biomarkers of the beta-amyloid and microtubule associated protein tau metabolism have proven the capacity to improve classification of subjects developing Alzheimer’s disease (AD). The blood plasma proteome was characterized to further elaborate upon the mechanisms involved and identify proteins that may improve classification of older adults developing an AD dementia.
Objective:
Identify and describe plasma protein expressions that best classify subjects with CSF-defined presence of AD pathology and cerebral amyloidosis.
Methods:
We performed a cross-sectional analysis of samples collected from community-dwelling elderly with (n = 72) or without (n = 48) cognitive impairment. CSF Aβ1-42, tau, and phosphorylated tau (P-tau181) were measured using ELISA, and mass spectrometry quantified the plasma proteomes. Presence of AD pathology was defined as CSF P-tau181/Aβ1-42 > 0.0779, and presence of amyloidosis was defined as CSF Aβ1-42 < 724 pg/mL.
Results:
Two hundred and forty-eight plasma proteins were quantified. Plasma proteins did not improve classification of the AD CSF biomarker profile in the whole sample. When the analysis was separately performed in the cognitively impaired individuals, the diagnosis accuracy of AD CSF profile was 88.9% with 19 plasma proteins included. Within the full cohort, there were 16 plasma proteins that improved diagnostic accuracy of cerebral amyloidosis to 92.4%.
Conclusion:
Plasma proteins improved classification accuracy of AD pathology in cognitively-impaired older adults and appeared representative of amyloid pathology. If confirmed, those candidates could serve as valuable blood biomarkers of the preclinical stages of AD or risk of developing AD.
PrinceM, BryceR, AlbaneseE, WimoA, RibeiroW, FerriCP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement9, 63–75.e2.
2.
MusiekES, HoltzmanDM (2015) Three dimensions of the amyloid hypothesis: Time, space and ‘wingmen’. NatNeurosci18, 800–806.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
5.
HenriksenK, O’BryantSE, HampelH, TrojanowskiJQ, MontineTJ, JerominA, BlennowK, LönneborgA, Wyss-CorayT, SoaresH, BazenetC, SjögrenM, HuW, LovestoneS, KarsdalMA, WeinerMW, Blood-Based Biomarker Interest Group (2014) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement10, 115–131.
6.
ListaS, FaltracoF, PrvulovicD, HampelH (2013) Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog Neurobiol101-102, 1–17.
7.
BairdAL, WestwoodS, LovestoneS (2015) Blood-based proteomic biomarkers of Alzheimer’s disease pathology. Front Neurol6, 236.
8.
JackCRJr, KnopmanDS, JagustWJ, PetersenRC, WeinerMW, AisenPS, ShawLM, VemuriP, WisteHJ, WeigandSD, LesnickTG, PankratzVS, DonohueMC, TrojanowskiJQ (2013) Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol12, 207–216.
9.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFR, VisserPJ, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, Van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, De LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, De MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
10.
DayonL, Núñez GalindoA, CorthésyJ, CominettiO, KussmannM (2014) Comprehensive and scalable highly automated MS-based proteomic workflow for clinical biomarker discovery in human plasma. J Proteome Res13, 3837–3845.
11.
CominettiO, Núñez GalindoA, CorthésyJ, Oller MorenoS, IrincheevaI, ValsesiaA, AstrupA, SarisWH, HagerJ, KussmannM, DayonL (2016) Proteomic biomarker discovery in 1000 human plasma samples with mass spectrometry. J Proteome Res15, 389–399.
12.
PoppJ, OikonomidiA, TautvydaitėD, DayonL, BacherM, MigliavaccaE, HenryH, KirklandR, SeverinI, WojcikJ, BowmanGL (2017) Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun62, 203–211.
13.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
14.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundLO, NordbergA, BäckmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DecarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, JormA, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment - Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
15.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
16.
BuschkeH, SliwinskiMJ, KuslanskyG, LiptonRB (1997) Diagnosis of early dementia by the Double Memory Test: Encoding specificity improves diagnostic sensitivity and specificity. Neurology48, 989–997.
17.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
18.
ZigmondAS, SnaithRP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand67, 361–370.
19.
JormAF, JacombPA (1989) The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms. Psychol Med19, 1015–1022.
20.
PoppJ, RiadM, FreymannK, JessenF (2007) Diagnostic lumbar puncture performed in the outpatient setting of a memory clinic. Frequency and risk factors of post-lumbar puncture headache. Nervenarzt78, 547–551.
21.
TautvydaitėD, AntoniettiJP, HenryH, von GuntenA, PoppJ (2017) Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology. J Psychiatr Res90, 12–20.
22.
DuitsFH, TeunissenCE, BouwmanFH, VisserPJ, MattssonN, ZetterbergH, BlennowK, HanssonO, MinthonL, AndreasenN, MarcussonJ, WallinA, RikkertMO, TsolakiM, ParnettiL, HerukkaSK, HampelH, De LeonMJ, SchröderJ, AarslandD, BlankensteinMA, ScheltensP, van der FlierWM (2014) The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?. Alzheimers Dement10, 713–723.
23.
YoudenWJ (1950) Index for rating diagnostic tests. Cancer3, 32–35.
24.
DayonL, SanchezJC (2012) Relative protein quantification by MS/MS using the tandem mass tag technology. Methods Mol Biol893, 115–127.
25.
TibshiraniR (2011) Regression shrinkage and selection via the lasso: A retrospective. J R Stat Soc Series B Stat Methodol73, 273–282.
26.
FriedmanJ, HastieT, TibshiraniR (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw33, 1–22.
27.
RobinX, TurckN, HainardA, TibertiN, LisacekF, SanchezJC, MüllerM (2011) pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics12, 77.
28.
DeLongER, DeLongDM, Clarke-PearsonDL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics44, 837–845.
OllerMoreno S, CominettiO, NúñezGalindo A, IrincheevaI, CorthésyJ, AstrupA, SarisWH, HagerJ, KussmannM, DayonL (2017) The differential plasma proteome of obese and overweight individuals undergoing a nutritional weight loss and maintenance intervention. Proteomics Clin Appl. doi: 10.1002/prca.201600150
32.
HuynhRA, MohanC (2017) Alzheimer’s disease: Biomarkers in the genome, blood, and cerebrospinal fluid. Front Neurol8, 102.
33.
FernandezAM, Torres-AlemánI (2012) The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci13, 225–239.
34.
ÅbergD, JohanssonP, IsgaardJ, WallinA, JohanssonJO, AndreassonU, BlennowK, ZetterbergH, ÅbergND, SvenssonJ (2015) Increased cerebrospinal fluid level of insulin-like growth factor-II in male patients with Alzheimer’s disease. J Alzheimers Dis48, 637–646.
35.
HertzeJ, NäggaK, MinthonL, HanssonO (2014) Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: An observational study. BMC Neurol14, 64.
36.
DoeckeJD, LawsSM, FauxNG, WilsonW, BurnhamSC, LamCP, MondalA, BedoJ, BushAI, BrownB, DeRuyck K, EllisKA, FowlerC, GuptaVB, HeadR, MacaulaySL, PertileK, RoweCC, RembachA, RodriguesM, RumbleR, SzoekeC, TaddeiK, TaddeiT, TrounsonB, AmesD, MastersCL, MartinsRN, Alzheimer’sDisease Neuroimaging Initiative, AustralianImaging Biomarker and Lifestyle Research Group (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol69, 1318–1325.
37.
ToledoJB, DaX, BhattP, WolkDA, ArnoldSE, ShawLM, TrojanowskiJQ, DavatzikosC, Alzheimer’sDisease Neuroimaging Initiative (2013) Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One8, e55531.
KolevMV, RusevaMM, HarrisCL, MorganBP, DonevRM (2009) Implication of complement system and its regulators in Alzheimer’s disease. Curr Neuropharmacol7, 1–8.
40.
HongS, Beja-GlasserVF, NfonoyimBM, FrouinA, LiS, RamakrishnanS, MerryKM, ShiQ, RosenthalA, BarresBA, LemereCA, SelkoeDJ, StevensB (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science352, 712–716.
41.
McGeerPL, McGeerEG (2002) The possible role of complement activation in Alzheimer disease. Trends Mol Med8, 519–523.
42.
BarembaumM, MorenoTA, LaBonneC, SechristJ, Bronner-FraserM (2000) Noelin-1 is a secreted glycoprotein involved in generation of the neural crest. Nat Cell Biol2, 219–225.
43.
GuptaVB, LawsSM, VillemagneVL, AmesD, BushAI, EllisKA, LuiJK, MastersC, RoweCC, SzoekeC, TaddeiK, MartinsRN, AIBLResearch Group (2011) Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology76, 1091–1098.
44.
RasmussenKL, Tybjærg-HansenA, NordestgaardBG, Frikke-SchmidtR (2015) Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol77, 301–311.
LuoG, ZhangX, Nilsson-EhleP, XuN (2004) Apolipoprotein M. Lipids Health Dis3, 21.
47.
KabbaraA, PayetN, CottelD, FrigardB, AmouyelP, LambertJC (2004) Exclusion of CYP46 and APOM as candidate genes for Alzheimer’s disease in a French population. Neurosci Lett363, 139–143.
48.
KhoonsariE, HäggmarkA, LönnbergM, MikusM, KilanderL, LannfeltL, BergquistJ, IngelssonM, NilssonP, KultimaK, ShevchenkoG (2016) Analysis of the cerebrospinal fluid proteome in Alzheimer’s disease. PLoS One11, e0150672.
49.
BellingerFP, HeQP, BellingerMT, LinY, RamanAV, WhiteLR, BerryMJ (2008) Association of selenoprotein P with Alzheimer’s pathology in human cortex. J Alzheimers Dis15, 465–472.
50.
TakemotoAS, BerryMJ, BellingerFP (2010) Role of selenoprotein P in Alzheimer’s disease.,S1-. Ethn Dis20, 92–95.
51.
BrewerGJ, KanzerSH, ZimmermanEA, CelminsDF, HeckmanSM, DickR (2010) Copper and ceruloplasmin abnormalities in Alzheimers disease. Am J Alzheimers Dis Other Demen25, 490–497.
52.
SnaedalJ, KristinssonJ, GunnarsdóttirS, ÓlafsdóttirÁ, BaldvinssonM, JóhannessonT (1998) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease. A case-control study. Dementia Geriatr CognDisord9, 239–242.
53.
KesslerH, PajonkFG, MeisserP, Schneider-AxmannT, HoffmannKH, SupprianT, HerrmannW, ObeidR, MulthaupG, FalkaiP, BayerTA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer’s disease. J Neural Transm (Vienna)113, 1763–1769.
54.
ParkJH, LeeDW, ParkKS (2014) Elevated serum copper and ceruloplasmin levels in Alzheimer’s disease. Asia Pac Psychiatry6, 38–45.
55.
Wyss-CorayT, RogersJ (2012) Inflammation in Alzheimer disease-A brief review of the science and clinical literature., a. Cold Spring Harb Perspect Med2, 006346–basic.
56.
EdwardsM, BalldinVH, HallJ, O’BryantS (2015) Molecular markers of neuropsychological functioning and Alzheimer’s disease. Alzheimers Dement (Amst)1, 61–66.
57.
NilssonK, GustafsonL, HultbergB (2011) C-reactive protein level is decreased in patients with Alzheimer’s disease and related to cognitive function and survival time. Clin Biochem44, 1205–1208.
YarchoanM, LounevaN, XieSX, SwensonFJ, HuW, SoaresH, TrojanowskiJQ, LeeVMY, KlingMA, ShawLM, Chen-PlotkinA, WolkDA, ArnoldSE (2013) Association of plasma C-reactive protein levels with the diagnosis of Alzheimer’s disease. J Neurol Sci333, 9–12.
60.
IjsselstijnL, DekkerLJM, StinglC, vander Weiden MM, HofmanA, KrosJM, KoudstaalPJ, SillevisSmitt PA, IkramMA, BretelerMM, LuiderTM (2011) Serum levels of pregnancy zone protein are elevated in presymptomatic Alzheimer’s disease. J Proteome Res10, 4902–4910.
61.
MullerM, SchupfN, ManlyJJ, MayeuxR, LuchsingerJA (2010) Sex hormone binding globulin and incident Alzheimer’s disease in elderly men and women. Neurobiol Aging31, 1758–1765.
62.
XuJ, XiaLL, SongN, ChenSD, WangG (2016) Testosterone, estradiol, and sex hormone-binding globulin in Alzheimer’s disease: A meta-analysis. Curr Alzheimer Res13, 215–222.
63.
MateosL, IsmailMA, Gil-BeaFJ, LeoniV, WinbladB, BjörkhemI, Cedazo-MínguezA (2011) Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer’s disease. J Alzheimers Dis24, 669–679.
